<DOC>
	<DOCNO>NCT01535066</DOCNO>
	<brief_summary>RATIONALE : Acupuncture may help relieve joint pain . PURPOSE : This randomized phase III trial study acupuncture see well work compare sham acupuncture waitlist treat patient joint pain related aromatase inhibitor patient early-stage breast cancer .</brief_summary>
	<brief_title>S1200 : Acupuncture , Sham Acupuncture , Wait List Joint Symptoms Related Aromatase Inhibitors Pts W/Early-Stage Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether true acupuncture administer twice weekly 6 week ( 8-12 session ) compare sham acupuncture waitlist control cause significant reduction joint pain related aromatase inhibitor ( AIs ) woman early-stage breast cancer measure Brief Pain Inventory-Short Form ( BPI-SF ) bad pain score 6 week . Secondary - To investigate effect true acupuncture administer twice weekly 6 week ( 8-12 session ) follow 6 weekly treatment ( 4-6 session ) maintenance ( 12-18 session total 12 week ) compare sham acupuncture waitlist control study population ; evaluation 12 24 week determine benefit additional 6 weekly acupuncture treatment maintenance determine durability response stop acupuncture , respectively ; evaluation 52 week determine long-term effect acupuncture adherence AIs . - To evaluate effect acupuncture BPI-SF bad pain , bad stiffness , pain severity , pain-related interference score 6 , 12 , 16 , 20 , 24 , 52 week . - To evaluate effect acupuncture Western Ontario McMaster Universities Osteoarthritis ( WOMAC ) index ( pain , stiffness , function ) hips knee 6 , 12 , 24 , 52 week . - To evaluate effect acupuncture Modified-Score Assessment Quantification Chronic Rheumatoid Affections Hands ( M-SACRAH ) ( pain , stiffness , function ) 6 , 12 , 24 , 52 week . - To evaluate effect acupuncture PROMIS Pain Impact-Short Form ( PROMIS PI-SF ) 6 , 12 , 24 , 52 week . - To evaluate effect acupuncture quality life ( QOL ) assess Functional Assessment Cancer Therapy-Endocrine Subscales ( FACT-ES ) 6 , 12 , 24 , 52 week . - To evaluate effect acupuncture functional test grip strength `` Timed Get Up Go '' ( TGUG ) test 6 , 12 , 24 , 52 week . - To evaluate effect acupuncture analgesic opioid use 2 , 4 , 6 , 12 , 16 , 20 , 24 , 52 week . - To evaluate effect acupuncture self-reported AI adherence 12 , 24 , 52 week . - To assess AI adherence via urine AI metabolite baseline , 24 , 52 week . - To evaluate effect acupuncture serum hormone ( estradiol , FSH , LH ) inflammatory biomarkers ( serum TNFα , IL-6 , IL-12 , CRP , urine c-telopeptides Type II collagen ( CTX-II ) 6 , 12 , 24 week . ( Exploratory ) - To evaluate whether polymorphisms CYP19A1 aromatase gene predict severity AI-related joint symptom . ( Exploratory ) - To assess safety tolerability acupuncture study population . OUTLINE : This multicenter study . Patients stratify accord study site . Patients randomize 1 3 treatment arm . - Arm I : Patients receive acupuncture twice weekly 6 week weekly 6 week . - Arm II : Patients receive sham acupuncture twice weekly 6 week weekly 6 week . - Arm III : Patients assign wait list 12 week . Patients complete Brief Pain Inventory-Short Form ( BPI-SF ) , Western Ontario McMaster Universities Osteoarthritis ( WOMAC ) Index , Modified-Score Assessment Quantification Chronic Rheumatoid Affections Hands ( M-SACRAH ) , PROMIS Pain Impact-Short Form ( PROMIS PI-SF ) , FACT-ES Trial Outcome Index , Aromatase Inhibitor Usage Form questionnaires baseline 6 , 12 , 24 52 week . Patients undergo blood sample collection baseline 6 , 12 , 24 week serum hormone ( estradiol , FSH , LH ) level , inflammatory marker ( TNFα , IL-6 , IL-12 , CRP ) , DNA analysis . Urine sample also collect baseline 24 52 week c-telopeptides Type II collagen aromatase inhibitor metabolites analysis . After completion study treatment , patient follow 24 52 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients must woman histologically confirm primary invasive carcinoma breast ( Stage I , II , III ) evidence metastatic disease ( M0 ) ; patient must undergo modified radical mastectomy breastsparing surgery ; patient must recover sideeffects surgery Patients must positive estrogen receptor ( ER ) and/or progesterone receptor ( PgR ) determine institutional standard Patients must currently take thirdgeneration aromatase inhibitor ( AI ) anastrozole , letrozole , exemestane least previous 90 day prior registration plan continue least additional 1 year registration ; patient may switch AIs provide stable dose least 90 day ; concurrent trastuzumab ( Herceptin ) allow Patients must complete S1200 Brief Pain InventoryShort Form ( BPISF ) within 14 day prior registration ; patient must worst pain score least 3 Brief Pain Inventory ( item # 2 ) start increase since start AI therapy Patients must willing submit blood urine sample serum hormone ( estradiol , FSH , LH ) , inflammatory biomarkers ( serum TNFα , IL6 , IL12 , CRP urine CTXII ) , urine AI metabolite , DNA analysis ( CYP19A1 ) , must give option consent use remain specimen future translational medicine study ; baseline sample must obtain prior begin intervention PATIENT CHARACTERISTICS : Patients must postmenopausal , define least one following : ≥ 12 month since last menstrual period Prior bilateral oophorectomy Current use gonadotropinreleasing hormone ( GnRH ) agonist Previous hysterectomy one ovaries leave place ( previous hysterectomy documentation bilateral oophorectomy unavailable ) AND folliclestimulating hormone ( FSH ) value consistent institutional normal value postmenopausal state ; patient age 55 , FSH level must obtain within 28 day prior registration Patients must Zubrod performance status 0 1 Patients must severe bleed disorder Patients must concurrent medical/arthritic disease could confound interfere evaluation pain efficacy include : inflammatory arthritis ( e.g. , rheumatoid arthritis , systemic lupus , spondyloarthropathy , psoriatic arthritis , polymyalgia rheumatica ) , gout , episodes acute monoarticular arthritis clinically consistent pseudogout , Paget disease affect study joint ( knees/hands ) , history septic arthritis avascular necrosis intraarticular fracture study joint , Wilson disease , hemochromatosis , alkaptonuria , primary osteochondromatosis Patients must history bone fracture surgery afflict knee and/or hand within 6 month prior registration Patients must history illness , opinion investigator , might confound result study pose additional risk patient Patients must able complete study questionnaire English Spanish No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , ductal carcinoma situ [ DCIS ] , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree &gt; 5 year PRIOR CONCURRENT THERAPY : See Disease Characteristics Patients must prior acupuncture treatment within past 12 month AIinduced joint symptom time Patients must narcotics within 14 day registration Patients must receive oral corticosteroid , intramuscular corticosteroid , intraarticular steroid within 28 day prior registration Patients must receive topical analgesic ( e.g. , capsaicin preparation ) analgesic ( e.g. , opiates tramadol , exception nonsteroidal antiinflammatory drug [ NSAIDs ] acetaminophen ) within 14 day prior registration Patients must receive implemented medical therapy , alternative therapy , physical therapy treatment joint pain/stiffness within 28 day prior registration ; therapeutic massage allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>pain</keyword>
</DOC>